Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- J&J Eyes Double-Digit Growth in Japan Pharma Biz from 2027, 50 Approvals by 2029
October 7, 2024
- Kyowa Kirin Drops Japan Filing for Lumicef for Systemic Sclerosis
October 4, 2024
- Daiichi Sankyo Espha to Launch Plaquenil AG in December
October 4, 2024
- Amitiza Claims Tripple Gold in August HP Rep Promotion Rankings: Intage
October 4, 2024
- PeptiDream, Curium Join Hands on Radionuclide Therapy for Prostate Cancer
October 3, 2024
- Orion to Take Over Divigel as Its 1st Product in Japan
October 3, 2024
- Ex-BMS Exec Sugita Tapped as President of Nxera Pharma Japan
October 2, 2024
- Shionogi Sole Distributor of Nxera’s Insomnia Med in Japan
October 2, 2024
- Meiji Rolls Out COVID Jab Kostaive in Japan
October 2, 2024
- Enhertu Gets Priority Review for HER2 Low or Ultralow Breast Cancer in US
October 2, 2024
- Pfizer Japan to Suspend Lower-Strength Version of Syphilis Drug
October 1, 2024
- Healios Again Delays Definitive MultiStem Deal with Nobelpharma
October 1, 2024
- Towa, SymBio/Eagle Settle Treakisym Patent Suit
October 1, 2024
- Nippon Kayaku Files Humira Biosimilar for nr-axSpA
October 1, 2024
- Astellas Touts Confirmed Safety and Antitumor Effects of Protein Degrader
September 30, 2024
- Sawai Ordered to Pay 3 Billion Yen in Damages in Teribone Suit, Set to Appeal
September 30, 2024
- 8 South Korean Biotechs Now Housed at Shonan iPark
September 30, 2024
- Shionogi Files Sage’s Depression Drug in Japan
September 30, 2024
- Asahi Kasei to Divest Diagnostics Biz to Nagase in July 2025
September 27, 2024
- Fujirebio Files Blood-Based Diagnostic Test for Alzheimer’s in US
September 27, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…